Advertisement

Topics

Amgen And Allergan Submit Biosimilar BLA For ABP 980 To FDA

09:23 EDT 31 Jul 2017 | FinanzNachrichten

THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and Allergan plc. (AGN) announced the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for ABP 980, a biosimilar...

Original Article: Amgen And Allergan Submit Biosimilar BLA For ABP 980 To FDA

NEXT ARTICLE

More From BioPortfolio on "Amgen And Allergan Submit Biosimilar BLA For ABP 980 To FDA"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...